Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study.

Weigel BJ, Blaney SM, Reid JM, Safgren SL, Bagatell R, Kersey J, Neglia JP, Ivy SP, Ingle AM, Whitesell L, Gilbertson RJ, Krailo M, Ames M, Adamson PC.

Clin Cancer Res. 2007 Mar 15;13(6):1789-93.

2.

Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.

Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, Zuhowski EG, Whitlock JA, Hunger SP, Narendran A, Katzenstein HM, Arceci RJ, Boklan J, Herzog CE, Whitesell L, Ivy SP, Trippett TM.

Clin Cancer Res. 2007 Mar 15;13(6):1783-8.

3.

Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.

Children's Oncology Group, Fouladi M, Furman WL, Chin T, Freeman BB 3rd, Dudkin L, Stewart CF, Krailo MD, Speights R, Ingle AM, Houghton PJ, Wright J, Adamson PC, Blaney SM.

J Clin Oncol. 2006 Aug 1;24(22):3678-85.

PMID:
16877737
4.

A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer.

Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL, Erlichman C.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6087-93.

5.

Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.

Saif MW, Erlichman C, Dragovich T, Mendelson D, Toft D, Burrows F, Storgard C, Von Hoff D.

Cancer Chemother Pharmacol. 2013 May;71(5):1345-55. doi: 10.1007/s00280-013-2134-9. Epub 2013 Apr 6.

PMID:
23564374
6.

Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.

Ramanathan RK, Egorin MJ, Eiseman JL, Ramalingam S, Friedland D, Agarwala SS, Ivy SP, Potter DM, Chatta G, Zuhowski EG, Stoller RG, Naret C, Guo J, Belani CP.

Clin Cancer Res. 2007 Mar 15;13(6):1769-74.

7.

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.

Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, DeLaCruz A, Curley T, Heller G, Larson S, Schwartz L, Egorin MJ, Rosen N, Scher HI.

Clin Cancer Res. 2007 Mar 15;13(6):1775-82.

8.

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.

Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg WD, Zajac-Kaye M, Chen M, Steinberg SM, Muir CA, Yancey MA, Horneffer YR, Juwara L, Melillo G, Ivy SP, Merino M, Neckers L, Steeg PS, Conley BA, Giaccone G, Doroshow JH, Murgo AJ.

Eur J Cancer. 2010 Jan;46(2):340-7. doi: 10.1016/j.ejca.2009.10.026. Epub 2009 Nov 27.

9.

Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.

Malempati S, Nicholson HS, Reid JM, Blaney SM, Ingle AM, Krailo M, Stork LC, Melemed AS, McGovern R, Safgren S, Ames MM, Adamson PC; Children's Oncology Group.

J Clin Oncol. 2007 Apr 20;25(12):1505-11. Erratum in: J Clin Oncol. 2008 Jan 1;26(1):165.

PMID:
17442992
10.

A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin.

Furth AF, Mandrekar SJ, Tan AD, Rau A, Felten SJ, Ames MM, Adjei AA, Erlichman C, Reid JM.

Cancer Chemother Pharmacol. 2008 Jan;61(1):39-45. Epub 2007 Mar 20.

PMID:
17909811
11.

Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.

Whitlock JA, Krailo M, Reid JM, Ruben SL, Ames MM, Owen W, Reaman G; Children's Oncology Group Study.

J Clin Oncol. 2005 Dec 20;23(36):9179-86.

PMID:
16361620
12.

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA.

J Clin Oncol. 2007 Dec 1;25(34):5410-7.

PMID:
18048823
13.

A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.

Weitman S, Langevin AM, Berkow RL, Thomas PJ, Hurwitz CA, Kraft AS, Dubowy RL, Smith DL, Bernstein M.

Clin Cancer Res. 1999 Sep;5(9):2344-8.

14.

Phase I study of everolimus in pediatric patients with refractory solid tumors.

Fouladi M, Laningham F, Wu J, O'Shaughnessy MA, Molina K, Broniscer A, Spunt SL, Luckett I, Stewart CF, Houghton PJ, Gilbertson RJ, Furman WL.

J Clin Oncol. 2007 Oct 20;25(30):4806-12.

PMID:
17947729
15.

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.

Hubbard J, Erlichman C, Toft DO, Qin R, Stensgard BA, Felten S, Ten Eyck C, Batzel G, Ivy SP, Haluska P.

Invest New Drugs. 2011 Jun;29(3):473-80. doi: 10.1007/s10637-009-9381-y. Epub 2010 Jan 15.

16.

Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumors.

Campone M, Isambert N, Bourbouloux E, Maury S, Monin-Baroille P, Berille J, Fumoleau P.

Cancer Chemother Pharmacol. 2007 Apr;59(5):689-95. Epub 2006 Oct 10.

PMID:
17031647
17.

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L, Wilson RH.

J Clin Oncol. 2005 Mar 20;23(9):1885-93.

PMID:
15774780
18.

Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.

Ramanathan RK, Trump DL, Eiseman JL, Belani CP, Agarwala SS, Zuhowski EG, Lan J, Potter DM, Ivy SP, Ramalingam S, Brufsky AM, Wong MK, Tutchko S, Egorin MJ.

Clin Cancer Res. 2005 May 1;11(9):3385-91.

19.

Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101.

Adamson PC, Blaney SM, Widemann BC, Kitchen B, Murphy RF, Hannah AL, Cropp GF, Patel M, Gillespie AF, Whitcomb PG, Balis FM.

Cancer Chemother Pharmacol. 2004 Jun;53(6):482-8. Epub 2004 Mar 4.

PMID:
14999430
20.

Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.

Rheingold SR, Hogarty MD, Blaney SM, Zwiebel JA, Sauk-Schubert C, Chandula R, Krailo MD, Adamson PC; Children's Oncology Group Study.

J Clin Oncol. 2007 Apr 20;25(12):1512-8.

PMID:
17442993

Supplemental Content

Support Center